<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03237728</url>
  </required_header>
  <id_info>
    <org_study_id>HR-KB104</org_study_id>
    <nct_id>NCT03237728</nct_id>
  </id_info>
  <brief_title>Study of Multiple-dose Kukoamine B Mesilate in Sepsis Patients</brief_title>
  <official_title>Randomized, Double-blind Placebo-controlled Clinical Study to Assess Safety, Tolerance, Pharmacokinetics, Pharmacodynamic of Multiple-dose Kukoamine B Mesilate in Sepsis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Chasesun Pharmaceutical Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Chasesun Pharmaceutical Co., LTD</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I study of multiple-dose Kukoamine B Mesilate in Sepsis Patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To Assess Safety, Tolerance, Pharmacokinetics, Pharmacodynamic of multiple-dose Kukoamine B
      Mesilate in Sepsis Patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Day-1 to Day8</time_frame>
    <description>AE, physical examination, monitoring of vital signs, Laboratory examination etc.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>0.06mg/kg,KB and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A:0.06mg/kg,Q8h,Day1-Day7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.12mg/kg,KB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B:0.12mg/kg,Q8h,Day1-Day7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.24mg/kg,KB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C:0.24mg/kg,Q8h,Day1-Day7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group D:Placebos,Q8h,Day1-Day7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.06mg/kg,KB</intervention_name>
    <description>0.06mg/kg,Q8h,Day1-Day7</description>
    <arm_group_label>0.06mg/kg,KB and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.12mg/kg,KB</intervention_name>
    <description>0.12mg/kg,Q8h,Day1-Day7</description>
    <arm_group_label>0.12mg/kg,KB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.24mg/,KB</intervention_name>
    <description>0.24mg/kg,Q8h,Day1-Day7</description>
    <arm_group_label>0.24mg/kg,KB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebos,Q8h,Day1-Day7</description>
    <arm_group_label>0.06mg/kg,KB and Placebo</arm_group_label>
    <arm_group_label>Placebos</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The age of ≥ 18 years of age and ≤ 70 years of age, gender is not limited;

          2. Confirmed or suspected bacterial infection (refer to Appendix 5);

          3. Infection-related organ failure does not exceed 24 hours; organ failure is defined as
             circulation, (SOFA) ≥ 3 points in at least one organ or system of the respiratory,
             kidney, liver, coagulation and central nervous system;

          4. The time interval between the selection of the test drug and the test drug is not more
             than 8 hours;

          5. Infertility test for women of childbearing age;

          6. Childbearing age within six months without child care plan and agreed to take
             effective measures during the study of contraception;

          7. Patients or legal representatives signed informed consent.

        Exclusion Criteria:

          1. Pregnant or lactating women, or unable to take effective measures of contraception;

          2. Patients are expected to live less than 28 days due to basic diseases, such as poor
             control of malignant tumor, cardiac arrest in 30 days, and end-stage lung disease.

          3. The patient has the following chronic organ dysfunction or immunosuppression (based on
             the chronic health scoring assessment of the APACHE II score) : a) heart: New York
             heart association cardiac function IV; B) breathing: chronic obstructive, obstructive,
             or vascular lung disease can lead to severe restrictions on activities, i.e. the
             inability to go upstairs or to do housework; Or clear chronic hypoxia, CO2 retention,
             secondary real erythrocyte, severe pulmonary hypertension (&gt; 40 mmHg) or respiratory
             muscle dependence; C) kidneys: receiving long-term dialysis; D) liver: liver cirrhosis
             confirmed by biopsy and clear portal hypertension; The upper digestive tract
             hemorrhage caused by portal hypertension; Or previous liver failure/hepatic
             encephalopathy/hepatic coma; E) of immune function: accept the treatment of impact
             resistance to infection, such as immune suppression therapy, chemotherapy, radiation
             therapy, or for a long time the recent use of high doses of hormones), or sickness
             impact resistance to infection, such as leukemia, lymphoma and AIDS);

          4. Solid organ or bone marrow transplantation;

          5. Plant survival status;

          6. The following conditions occurred within 4 weeks prior to infection: a) acute
             pulmonary embolism; B) transfusion response; C) acute coronary syndrome;

          7. Confirmed or highly suspected of acute infectious diseases such as viral hepatitis
             activity and active tuberculosis;

          8. Patients with sinus bradycardia (less than 60 per minute);

          9. Severe anemia (hemoglobin &lt; 7.0 g/dL);

         10. Uncontrolled bleeding in the past 24 hours;

         11. Large area burns or chemical burns (III degree burns area &gt; 30% BSA);

         12. The average arterial pressure was &lt; 65 mmHg after adequate liquid resuscitation and
             vasoactive drug therapy.

         13. Acute myeloid hematopoiesis was characterized by a lack of severe granulocytes (ANC &lt;
             500 / mm3), or severe thrombocytopenia (&lt; 20,000 / mm3);

         14. Allergic to the active ingredient or its auxiliary materials;

         15. The medication patients are using may severely affect the metabolism of the drug;

         16. Patients and (or) legal representatives have signed an unresuscitation (DNR), or
             decided to withdraw life support (withdraw) or restrict life support for the intensity
             (of the patient) and sign the informed consent form;

         17. Participated in clinical intervention test in 3 months;

         18. The subject is a researcher or his immediate family member, or may have improper
             informed consent;

         19. The attending physician considers it inappropriate for the patient to participate in
             this test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bin Du, Doctor</last_name>
    <phone>+86 010-69155036</phone>
    <email>dubin98@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shuai Chen, Bachelor</last_name>
    <phone>+86 022-59693561</phone>
    <email>18600050139@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuai Chen, Bachelor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2017</study_first_submitted>
  <study_first_submitted_qc>August 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2017</study_first_posted>
  <last_update_submitted>April 28, 2018</last_update_submitted>
  <last_update_submitted_qc>April 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

